Mark T. Fleming, MD, Talks Use of 18F-rhPSMA-7.3 for PET/CT in Recurrent Prostate Cancer


Mark T. Fleming, MD, spoke about how use of 18F-rhPSMA-7.3 for PET/CT scans in patients with recurrent prostate cancer bests conventional imaging.

At the American Urological Association 2022 Annual Meeting, CancerNetwork® spoke with Mark T. Fleming, MD, medical director for the US Oncology Genitourinary Research Committee, Division Chief of Eastern Virginia Medical School Department of Hematology & Oncology, and president of medical staff at Sentara Careplex Hospital, who discussed use of 18F-rhPSMA-7.3 for PET/CT imaging and how use of the agent led to a more frequent baseline post-scan disease upstaging in men with recurrent prostate cancer compared with conventional imaging.

Results of the phase 3 SPOTLIGHT trial (NCT04186845) showed that 18F-rhPSMA-7.3 resulted in a 45% to 47% correct detection rate, defined as the rate at which patients have at least 1 true positive PET finding in comparison with the Standard of Truth histopathology or confirmatory conventional imaging.


It showed that we are able to upstage patients and find diseases that were missed. [Negative findings on conventional imaging give] a false sense of reassurance to patients that they didn’t have a recurrence of the disease. The increase in the upstaging of patients was dramatic. Compared with other PET imaging, this wasn’t a comparator [trial, but rather] an exploratory trial. There are other agents out there, but these are very encouraging data. I had many patients in this trial, and I was very impressed by the data that we saw, [especially] in my own patients.


Fleming MT. Impact of 18F-rhPSMA-7.3 PET on upstaging of patients with prostate cancer recurrence: results from the prospective, phase 3, multicenter, SPOTLIGHT study. Presented at: 2022 AUA Annual Meeting; May 13-16, 2022; New Orleans, LA. Abstract PLLBA-02.

Related Videos
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD.
Alicia K. Morgans, MD, MPH, from Dana-Farber Cancer Institute indicates that patients with non-metastatic castration-resistant prostate cancer are able to stay on treatment for long periods of time with darolutamide vs enzalutamide and apalutamide.
Andrew J. Armstrong, MD, MSc, spoke about the recent approval of olaparib plus abiraterone acetate and prednisone in patients with BRCA-mutant metastatic castration-resistant prostate cancer.
Related Content